Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer

Journal of Controlled Release

Volumn 244, Issue , 2016, Pages 63-73

  Xiong, Yang ^a,b   Zhao, Yi ^a   Miao, Lei ^a   Lin, C Michael ^a   Huang, Leaf ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Core membrane nanoparticle; Non small cell lung cancer; Polymeric metformin

Indexed keywords

BIOLOGICAL ORGANS; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; ENZYME ACTIVITY; LIPOSOMES; MAMMALS; NANOPARTICLES; TARGETED DRUG DELIVERY; TUMORS;

AMP-ACTIVATED PROTEIN KINASE; CATIONIC LIPOSOMES; CIS-PLATIN; GROWTH SUPPRESSIONS; METFORMINS; NON SMALL CELL LUNG CANCER; POLYGLUTAMIC ACIDS; TUMOR ACCUMULATION;

DRUG PRODUCTS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AMIDE; ANISAMIDE AMINOETHYL; CHOLESTEROL; CISPLATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; LIPOSOME; MACROGOL; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; NANOPARTICLE; POLYGLUTAMIC ACID; POLYMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL-DISTEAROYLPHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; DISPERSITY; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MOUSE; NANOENCAPSULATION; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; LUNG TUMOR; NUDE MOUSE; PATHOLOGY; SURFACE PROPERTY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG LIBERATION; DRUG SYNERGISM; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; METFORMIN; MICE; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84997096200     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.11.005     Document Type: Article

References (43)

1. [1] http://www.wcrf.org/cancerstatistics/worldcancerstatistics.php.2012; Available at: http://www.crf.org/cancer statistics/worldcancerstatistics.php. (Accessed March 2014).
2. [2] Spiro, S.G., Tanner, N.T., Silvestri, G.A., Janes, S.M., Lim, E., Vansteenkiste, J.F., Pirker, R., Lung cancer: progress in diagnosis, staging and therapy. Respirology 15 (2010), 44–50.
3. [3] Surveillance, Epidemiology, Sur and End Results [SEER] incidence and National Center for HealthStatistics [NHCS] mortality statistics. Available at: http://www.cancer.gov/cancertopics/types/lung/cancer-survival-prognosis. (Last accessed 4 August 2014).
4. [4] De Angelis, R., Sant, M., Coleman, M.P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O., Brenner, H., Ardanaz, E., Bielska-Lasota, M., Engholm, G., Nennecke, A., Siesling, S., Berrino, F., Capocaccia, R., Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 15 (2014), 23–34.
5. [5] Yin, J.Y., Huang, Q., Zhao, Y.C., Zhou, H.H., Liu, Z.Q., Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One, 7, 2012, e38150.
6. [6] N.C. Institute, Non-small cell lung cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page10, 2014.
7. [7] Dingemans, A.M., Mellema, W.W., Groen, H.J., van Wijk, A., Burgers, S.A., Kunst, P.W., Thunnissen, E., Heideman, D.A., Smit, E.F., A phase II study of sorafenib in patients with platinum-pretreated, advanced (stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin. Cancer Res. 19 (2013), 743–751.
8. [8] Morgillo, F., Della, C.M.C., Festino, L., Manzo, A., Martinelli, E., Troiani, T., Capuano, A., Ciardiello, F., Metformin in lung cancer rationale for a combination therapy. Expert Opin. Investig. Drugs 22 (2013), 1401–1409.
9. [9] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001), 1167–1174.
10. [10] Dowling, R.J., Zakikhani, M., Fantus, I.G., Pollak, M., Sonenberg, N., Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67 (2007), 10804–10812.
11. [11] Lin, C.C., Yeh, H.H., Huang, W.L., Yan, J.J., Lai, W.W., Su, W.P., Chen, H.H., Su, W.C., Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am. J. Respir. Cell Mol. Biol. 49 (2013), 241–250.
12. [12] Teixeira, S.F., Madeira, K.P., Daltoé, R.D., Silva, I.V., Rangel, L.B., Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells. J. Bras. Pneumol. 39:6 (2013), 644–649.
13. [13] Guo, S., Wang, Y., Miao, L., Xu, Z., Lin, C.M., Zhang, Y., Huang, L., Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 7 (2013), 9896–9904.
14. [14] Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., K., K., Matsumura, Y., Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors can eradicate solid tumors in mice. Cancer Res. 63 (2003), 8977–8983.
15. [15] Boulikas, T., Clinical overview on Lipoplatin- a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18 (2009), 1197–1218.
16. [16] Plummer, R., Wilson, R.H., Calvert, H., Boddy, A.V., Griffin, M., Sludden, J., Tilby, M.J., Eatock, M., Pearson, D.G., Ottley, C.J., Matsumura, Y., Kataoka, K., Nishiya, T., A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104 (2011), 593–598.
17. [17] Miao, L., Guo, S., Zhang, J., Kim, W.Y., Huang, L., Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 24 (2014), 6601–6611.
18. [18] Zhao, Y., Wang, W., Guo, S., Wang, Y., Miao, L., Xiong, Y., Huang, L., Polymetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat. Commun., 7, 2016, 11822.
19. [19] Ye, H., Jin, L., Hu, R., Yi, Z., Li, J., Wu, Y., Xi, X., Wu, Z., Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27 (2006), 5958–5965.
20. [20] Banerjee, R., Tyagi, P., Li, S., Huang, L., Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer 112 (2004), 693–700.
21. [21] Guo, S., Miao, L., Wang, Y., Huang, L., Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J. Control. Release 174 (2014), 137–142.
22. [22] Zhang, Y., Kim, W.Y., Huang, L., Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 34 (2013), 3447–3458.
23. [23] Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22 (1984), 27–55.
24. [24] Han, Y., He, Z., Schulz, A., Bronich, T.K., Jordan, R., Luxenhofer, R., Kabanov, A.V., Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. Mol. Pharm. 9 (2012), 2302–2313.
25. [25] Miao, L., Wang, Y., Lin, C.M., Xiong, Y., Chen, N., Zhang, L., Kim, W.Y., Huang, L., Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J. Control. Release 217 (2015), 27–41.
26. [26] Luo, C., Miao, L., Zhao, Y., Musetti, S., Wang, Y., Shi, K., Huang, L., A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials 102 (2016), 239–248.
27. [27] Li, S.D., Huang, L., Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 145 (2010), 178–181.
28. [28] De Palma, R., Peeters, S., Van Bael, M.J., Van den Rul, H., Bonroy, K., Laureyn, W., Mullens, J., Borghs, G., Maes, G., Silane ligand exchange to make hydrophobic superparamagnetic nanoparticles water-dispersible. Chem. Mater. 19 (2007), 1821–1831.
29. [29] Jenkins, S.I., Pickard, M.R., Furness, D.N., Yiu, H.H., Chari, D.M., Differences in magnetic particle uptake by CNS neuroglial subclasses: implications for neural tissue engineering. Nanomedicine 8 (2012), 951–968.
30. [30] Xiong, Y., Jiang, W., Shen, Y., Li, H., Sun, C., Ouahab, A., Tu, J., A poly(gamma, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 33 (2012), 7182–7193.
31. [31] Wang, Y., Miao, L., Satterlee, A., Huang, L., Delivery of oligonucleotides with lipid nanoparticles. Adv. Drug Deliv. Rev. 87 (2015), 68–80.
32. [32] Vasey, P.A., Kaye, S.B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A.H., Murray, L.S., Hilditch, T.E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., Cassidy, J., Phase I clinical and pharmacokinetic study of PK1 [N-(2Hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents—drug-polymer conjugates. Clin. Cancer Res. 5 (1999), 83–94.
33. [33] Mochida, Y., Cabral, H., Miura, Y., Albertini, F., Fukushima, S., Osada, K., Nishiyama, N., Kataoka, K., Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. ACS Nano 8 (2015), 6724–6738.
34. [34] Song, P., Kwon, Y., Yea, K., Moon, H.Y., Yoon, J.H., Ghim, J., Hyun, H., Kim, D., Koh, A., Berggren, P.O., Suh, P.G., Ryu, S.H., Apolipoprotein a1 increases mitochondrial biogenesis through AMP-activated protein kinase. Cell. Signal. 27 (2015), 1873–1881.
35. [35] LeRoith, D., Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics. 2012, Humana Press, New York.
36. [36] Vallianou, N.G., Evangelopoulos, A., Kazazis, C., Metformin and cancer. Rev. Diabet. Stud. 10 (2013), 228–235.
37. [37] Faubert, B., Vincent, E.E., Poffenberger, M.C., Jones, R.G., The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 356 (2015), 165–170.
38. [38] Lopez-Cotarelo, P., Escribano-Diaz, C., Gonzalez-Bethencourt, I.L., Gomez-Moreira, C., Deguiz, M.L., Torres-Bacete, J., Gomez-Cabanas, L., Fernandez-Barrera, J., Delgado-Martin, C., Mellado, M., Regueiro, J.R., Miranda-Carus, M.E., Rodriguez-Fernandez, J.L., A novel MEK-ERK-AMPK signaling axis controls chemokine receptor CCR7-dependent survival in human mature dendritic cells. J. Biol. Chem. 290 (2015), 827–840.
39. [39] Mihaylova, M.M., Shaw, R.J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13 (2011), 1016–1023.
40. [40] Naoki, K., Chiharu, T., Sushila, D., Christine, R., Yoshino, K., Kenta, H., Bruce, E.K., Lee, A.W., Osamu, M., Kazuyoshi, Y., A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8 (2003), 65–79.
41. [41] Zhang, Y., Peng, L., Mumper, R.J., Huang, L., Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 34 (2013), 8459–8468.
42. [42] Mazzoni, F., Cecere, F.L., Meoni, G., Giuliani, C., Boni, L., Camerini, A., Lucchesi, S., Martella, F., Amoroso, D., Lucherini, E., Torricelli, F., Di Costanzo, F., Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer 82 (2013), 288–293.
43. [43] Liu, Y., Bernauer, A.M., Yingling, C.M., Belinsky, S.A., HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 33 (2012), 1187–1192.